Joseph Papa

With more than 30 years of experience in the healthcare sector, Joseph Papa most recently served as CEO and Chairman at Bausch + Lomb, a global eye health company. During his tenure, the Company successfully completed its NYSE IPO, raising $630 million in May 2022.

Throughout his career, Papa has held various leadership roles within the pharmaceutical industry. He held the positions of CEO and Chairman at Valeant, a multinational pharmaceutical company that later rebranded as Bausch Health and, before this, at Perrigo, a private-label over-the-counter pharmaceuticals manufacturer. He also led the pharmaceutical and technologies services division at Cardinal Health, a healthcare services and distribution company. Before these roles, Papa served as President and COO at Watson Pharmaceuticals, President of the US business at Searle / Pharmacia and spent 14 years at Novartis Pharmaceuticals, working in the US and Switzerland. During his time at Novartis and Searle / Pharmacia, he played a significant role in the successful launch of several products, including Lotrel®, Divovan®, and Celebrex®.

In recognition of his accomplishments, Harvard Business Review ranked him 47th on their list of “Best Performing CEOs in the World” in 2014.